22nd Apr 2026 07:00
Creo Medical Group plc
("Creo", the "Company" or the "Group")
Positive Q1 trading update
Strong trading momentum continues with 60% year-on-year revenue growth in Q1
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, provides a trading update for the three months ended 31 March 2026 (Q1 FY26).
Further to the update provided on 20 January 2026, the Company's growth momentum for the year ended 31 December 2025 (FY25) has continued, with a strong trading performance in Q1 FY26. Year-on-year revenue growth (Q1 FY26 vs Q1 FY25) was c.60%, the upper limit of management's expectations. This performance underpins management's view that the Company is on track to deliver 40% to 60% full year revenue growth during FY 2026.
Along with top line growth, management continues to focus on improving the operational efficiency of the business. Following the announcement of the sale and outsourcing of its manufacturing operations announced on 16 April 2026, the Company is expected to reduce underlying operating costs by 15% compared to FY25 on an annualised basis. Commercial progress continues to be made across the Company's product portfolio, supported by excellent clinical validation.
Creo's full year results for 2025 are expected to be announced in May 2026.
For further information please contact:
Creo Medical Group plc | www.creomedical.com | |
Richard Craven, Company Secretary | Via Walbrook PR | |
Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser) Duncan Monteith / Sher Shah | +44 (0)20 7260 1000 | |
| ||
Shore Capital (Joint Broker) Daniel Bush / Lucy Bowden
| +44 (0)20 7408 4090 | |
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or [email protected] | |
Paul McManus / Alice Woodings
| Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
Related Shares:
Creo Medical